PARP4 and lung carcinoma: Similarly, PARP4 KO models show increased tumorigenicity in lung cancer cells [53] and higher proliferation in the HCC1143 cell line of breast ductal carcinoma [54], indicating a tumor-suppressive role for these MARTs.